According to the UK Health Security Agency, exciting findings from the first UK real-world study by UKHSA show significantly increased protection against symptomatic disease from the Pfizer-BioNTech vaccine booster dose in individuals aged 50 and above.
The results show that 2 weeks after receiving a booster dose, protection against symptomatic infection in adults aged 50 years and over was 93.1% in those with AstraZeneca as their primary course and 94.0% for Pfizer-BioNTech.
This is wonderful news. Well done to ALL involved in the vaccination programme!
If you would like to read the article, click the link here.